CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab

Murtaza Khan; Douglas E. Ney; Bette K. Kleinschmidt-DeMasters; Lindsay Horton; Enrique Alvarez; Amanda L. Piquet

doi:10.1212/CPJ.0000000000000639

CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab

Murtaza Khan, Douglas E. Ney, Bette K. Kleinschmidt-DeMasters, Lindsay Horton, Enrique Alvarez, Amanda L. Piquet

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	273-276
Number of pages	4
Journal	Neurology: Clinical Practice
Volume	9
Issue number	3
DOIs	https://doi.org/10.1212/CPJ.0000000000000639
State	Published - Jun 1 2019
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/CPJ.0000000000000639

Cite this

@article{f0d937038207432eb34ee1ab331bb54d,

title = "CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab",

author = "Murtaza Khan and Ney, {Douglas E.} and Kleinschmidt-DeMasters, {Bette K.} and Lindsay Horton and Enrique Alvarez and Piquet, {Amanda L.}",

note = "Funding Information: M. Khan reports no disclosures. D.E. Ney received honoraria from consulting on DSMB for DNAtrix, Inc. B.K. Kleinschmidt-DeMasters and L. Horton report no disclosures. E. Alvarez has received research grants from Acorda, Biogen, Novartis, and Rocky Mountain MS Center and consulting honoraria from Actelion, Biogen, Celgene, Genentech, Genzyme, Teva, Novartis, and TG Therapeutics. A.L. Piquet has received research funding from the Drake Family. Outside of this work, Dr. Piquet reports honorarium from MedLink and consulting honoraria for serving on a scientific advisory board from Sanofi Gen-zyme. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.",

year = "2019",

month = jun,

day = "1",

doi = "10.1212/CPJ.0000000000000639",

language = "English (US)",

volume = "9",

pages = "273--276",

journal = "Neurology: Clinical Practice",

issn = "2163-0402",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab

AU - Khan, Murtaza

AU - Ney, Douglas E.

AU - Kleinschmidt-DeMasters, Bette K.

AU - Horton, Lindsay

AU - Alvarez, Enrique

AU - Piquet, Amanda L.

N1 - Funding Information: M. Khan reports no disclosures. D.E. Ney received honoraria from consulting on DSMB for DNAtrix, Inc. B.K. Kleinschmidt-DeMasters and L. Horton report no disclosures. E. Alvarez has received research grants from Acorda, Biogen, Novartis, and Rocky Mountain MS Center and consulting honoraria from Actelion, Biogen, Celgene, Genentech, Genzyme, Teva, Novartis, and TG Therapeutics. A.L. Piquet has received research funding from the Drake Family. Outside of this work, Dr. Piquet reports honorarium from MedLink and consulting honoraria for serving on a scientific advisory board from Sanofi Gen-zyme. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.

PY - 2019/6/1

Y1 - 2019/6/1

UR - http://www.scopus.com/inward/record.url?scp=85070506337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070506337&partnerID=8YFLogxK

U2 - 10.1212/CPJ.0000000000000639

DO - 10.1212/CPJ.0000000000000639

M3 - Article

C2 - 31341717

AN - SCOPUS:85070506337

SN - 2163-0402

VL - 9

SP - 273

EP - 276

JO - Neurology: Clinical Practice

JF - Neurology: Clinical Practice

IS - 3

ER -

CNS atypical T-cell lymphoproliferative disease following treatment with alemtuzumab

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this